Vigilant Capital Management Has Trimmed Cvs Health (CVS) Holding; Platinum Investment Management LTD Lifted Its Five Prime Therapeutics (FPRX) Position

CVS Health Corporation (NYSE:CVS) Logo

Vigilant Capital Management Llc decreased Cvs Health Corp (CVS) stake by 99.38% reported in 2018Q1 SEC filing. Vigilant Capital Management Llc sold 55,991 shares as Cvs Health Corp (CVS)’s stock declined 3.22%. The Vigilant Capital Management Llc holds 347 shares with $22,000 value, down from 56,338 last quarter. Cvs Health Corp now has $73.38B valuation. The stock increased 1.55% or $1.1 during the last trading session, reaching $72.18. About 9.11M shares traded or 4.81% up from the average. CVS Health Corporation (NYSE:CVS) has declined 13.06% since June 23, 2017 and is downtrending. It has underperformed by 25.63% the S&P500. Some Historical CVS News: 02/05/2018 – CVS CONFIRMS 2018 FULL YEAR OUTLOOK; 13/03/2018 – CVS Health and Aetna shareholders will vote today on the drugstore chain’s proposed $69 billion acquisition of the health insurer; 16/03/2018 – CVS to offer GSK’s new shingles vaccine at stores nationwide; 28/03/2018 – Walgreens retail sales decline overshadows pharmacy business strength; 08/03/2018 – CVS HEALTH TO SUPPLEMENT JOINT PROXY STATEMENT/PROSPECTUS; 09/04/2018 – TABLE-CVS Bay 2687.T -2017/18 parent forecast; 06/03/2018 – CVS jumbo bond attracts record $121bn in book orders; 28/03/2018 – GOTTLIEB SAYS NEW POLICIES WILL INCLUDE TIGHTENING VARIABILITY ALLOWED IN ORIGINAL BIOLOGICAL DRUGS; 02/05/2018 – CVS Health 1Q EPS 98c; 27/03/2018 – Rep. Davis: Employees at CVS, Best Buy, & Starbucks All Seeing Benefits of Tax Reform

Platinum Investment Management Ltd increased Five Prime Therapeutics Inc (FPRX) stake by 50% reported in 2018Q1 SEC filing. Platinum Investment Management Ltd acquired 31,400 shares as Five Prime Therapeutics Inc (FPRX)’s stock declined 1.07%. The Platinum Investment Management Ltd holds 94,200 shares with $1.62 million value, up from 62,800 last quarter. Five Prime Therapeutics Inc now has $611.94M valuation. The stock increased 1.46% or $0.25 during the last trading session, reaching $17.38. About 302,405 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 37.93% since June 23, 2017 and is downtrending. It has underperformed by 50.50% the S&P500. Some Historical FPRX News: 28/03/2018 – Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150; 03/04/2018 – PERSONAL GENOME, FIVE PRIME IN PACT FOR DIAGNOSTIC ASSAY; 30/05/2018 – Five Prime Therapeutics Announces Collaboration With Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates; 13/03/2018 – FIVE PRIME THERAPEUTICS INC FPRX.O SAYS CFO MARC BELSKY RESIGNED; 10/04/2018 – FIVE PRIME TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL; 08/05/2018 – Five Prime Therapeutics Expects 2018 Net Cash Used in Operating Activities to Be Less Than $135 M; 08/05/2018 – FIVE PRIME THERAPEUTICS INC – EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE LESS THAN $135 MLN; 30/05/2018 – FIVE PRIME PACT TO DEVELOP IHC COMPANION DIAGNOSTIC ASSAY; 03/04/2018 – Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics’ Targeted Immuno-Oncology Drug Candidate Bemarituzumab; 19/03/2018 – Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform

Investors sentiment increased to 0.9 in Q1 2018. Its up 0.18, from 0.72 in 2017Q4. It improved, as 97 investors sold CVS shares while 512 reduced holdings. 117 funds opened positions while 431 raised stakes. 821.03 million shares or 0.67% more from 815.59 million shares in 2017Q4 were reported. The Texas-based Oxbow Advisors Ltd Llc has invested 0.16% in CVS Health Corporation (NYSE:CVS). The California-based Eqis has invested 0.16% in CVS Health Corporation (NYSE:CVS). Canada Pension Plan Investment Board holds 2.43 million shares. Neumann Cap Mngmt Limited Co stated it has 53,423 shares. Keybank Association Oh holds 0.13% of its portfolio in CVS Health Corporation (NYSE:CVS) for 346,330 shares. Da Davidson invested in 0.67% or 522,119 shares. Palouse Management invested in 82,338 shares. Lifeplan Gru invested in 0% or 42 shares. Afam Incorporated reported 0.3% in CVS Health Corporation (NYSE:CVS). Phocas Finance Corp stated it has 0% of its portfolio in CVS Health Corporation (NYSE:CVS). Winch Advisory Limited Liability Corporation holds 0% of its portfolio in CVS Health Corporation (NYSE:CVS) for 42 shares. Raymond James Trust Na accumulated 130,494 shares. Tiemann Investment Lc has 0.21% invested in CVS Health Corporation (NYSE:CVS). Sabal Tru has 4,924 shares. Bank Of America Corp De has invested 0.16% in CVS Health Corporation (NYSE:CVS).

More notable recent CVS Health Corporation (NYSE:CVS) news were published by: which released: “CVS And Aetna Are Changing The Healthcare Paradigm” on June 18, 2018, also with their article: “Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today” published on June 19, 2018, published: “CVS Is a Massive Bargain” on June 22, 2018. More interesting news about CVS Health Corporation (NYSE:CVS) were released by: and their article: “2 Incredibly Cheap Value Stocks to Buy Now” published on June 22, 2018 as well as‘s news article titled: “CVS Health Expands Safe Drug Disposal at CVS Pharmacy Locations in Arizona to Help Combat Opioid Abuse” with publication date: June 20, 2018.

Vigilant Capital Management Llc increased Walgreen Boots Alliance Inc Com stake by 9,580 shares to 10,090 valued at $661,000 in 2018Q1. It also upped Schwab Fundamental Intl Lg Co Etf (FNDF) stake by 66,495 shares and now owns 1.47M shares. Us Bancorp (NYSE:USB) was raised too.

Since February 16, 2018, it had 2 insider purchases, and 1 sale for $713,454 activity. The insider Foulkes Helena sold 19,965 shares worth $1.42M. DORMAN DAVID W also bought $1.51 million worth of CVS Health Corporation (NYSE:CVS) on Friday, May 4. BROWN C DAVID II had bought 10,000 shares worth $619,900.

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health has $132 highest and $73 lowest target. $96.05’s average target is 33.07% above currents $72.18 stock price. CVS Health had 77 analyst reports since July 22, 2015 according to SRatingsIntel. Citigroup maintained CVS Health Corporation (NYSE:CVS) on Monday, November 13 with “Neutral” rating. The company was maintained on Wednesday, January 24 by Mizuho. The firm has “Hold” rating given on Wednesday, January 17 by Robert W. Baird. The stock has “Hold” rating by Wolfe Research on Wednesday, August 16. The rating was downgraded by Atlantic Securities to “Neutral” on Monday, February 6. The firm has “Buy” rating given on Tuesday, June 13 by Cowen & Co. On Wednesday, August 19 the stock rating was reinitiated by Evercore with “Buy”. The rating was downgraded by Robert W. Baird on Thursday, February 2 to “Neutral”. On Thursday, June 23 the stock rating was maintained by Mizuho with “Buy”. The rating was maintained by Citigroup with “Neutral” on Monday, May 9.

Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on August, 14. They expect $1.61 EPS, up 21.05% or $0.28 from last year’s $1.33 per share. CVS’s profit will be $1.64 billion for 11.21 P/E if the $1.61 EPS becomes a reality. After $1.48 actual EPS reported by CVS Health Corporation for the previous quarter, Wall Street now forecasts 8.78% EPS growth.

Platinum Investment Management Ltd decreased Alphabet Inc stake by 17,500 shares to 161,502 valued at $167.50 million in 2018Q1. It also reduced Peabody Energy Corp New stake by 393,100 shares and now owns 3.39 million shares. Incyte Corp (NASDAQ:INCY) was reduced too.

Among 14 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Five Prime Therapeutics has $75 highest and $17 lowest target. $35.82’s average target is 106.10% above currents $17.38 stock price. Five Prime Therapeutics had 28 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was initiated by BMO Capital Markets on Tuesday, April 12 with “Market Perform”. The firm has “Outperform” rating by Oppenheimer given on Monday, October 19. BMO Capital Markets maintained the shares of FPRX in report on Tuesday, November 7 with “Outperform” rating. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) earned “Buy” rating by Guggenheim on Thursday, February 15. On Tuesday, August 11 the stock rating was upgraded by Zacks to “Sell”. The stock has “Outperform” rating by Credit Suisse on Friday, March 11. The firm has “Outperform” rating given on Thursday, January 21 by Credit Suisse. BMO Capital Markets maintained it with “Outperform” rating and $60 target in Wednesday, February 28 report. As per Friday, August 21, the company rating was upgraded by Zacks. The rating was maintained by BMO Capital Markets on Monday, June 5 with “Hold”.

Investors sentiment increased to 2.33 in 2018 Q1. Its up 0.99, from 1.34 in 2017Q4. It improved, as 21 investors sold FPRX shares while 12 reduced holdings. 21 funds opened positions while 56 raised stakes. 31.62 million shares or 24.14% more from 25.47 million shares in 2017Q4 were reported. Teachers Retirement System Of The State Of Kentucky stated it has 0.01% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Eventide Asset Mngmt Ltd Company invested in 0.08% or 105,000 shares. Cubist Systematic Strategies Lc holds 0.01% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 11,163 shares. Citigroup reported 21,053 shares stake. Quantbot Technologies LP stated it has 7,347 shares or 0.01% of all its holdings. Fifth Third Comml Bank holds 300 shares. Morgan Stanley invested in 0% or 94,705 shares. Art Advsr Limited Liability Company has 158,769 shares. Prelude Capital Ltd Liability Co has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Connor Clark Lunn Invest stated it has 30,375 shares or 0% of all its holdings. 46,439 are held by Credit Suisse Ag. Great Point Partners Ltd Liability Company reported 868,100 shares stake. Manufacturers Life Ins The holds 0% or 25,032 shares in its portfolio. United Kingdom-based Pictet Asset Management Limited has invested 0.02% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Ecor1 Cap Limited Co holds 2.14% or 1.24 million shares in its portfolio.

More recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: which released: “Five Prime Therapeutics (FPRX) Announces Pact with Roche to Develop Companion Diagnostics for Targeted Immuno …” on May 30, 2018. Also published the news titled: “5 Top-Ranked High-Beta Stocks to Play the Roaring Market” on June 07, 2018.‘s news article titled: “Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting” with publication date: June 03, 2018 was also an interesting one.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart